Ritter Pharmaceuticals Inc (NASDAQ:RTTR) Short Interest Up 534.5% in January

Share on StockTwits

Ritter Pharmaceuticals Inc (NASDAQ:RTTR) was the target of a large growth in short interest in the month of January. As of January 15th, there was short interest totalling 708,100 shares, a growth of 534.5% from the December 31st total of 111,600 shares. Based on an average daily trading volume, of 2,160,000 shares, the days-to-cover ratio is currently 0.3 days. Approximately 7.7% of the shares of the stock are short sold.

Shares of Ritter Pharmaceuticals stock remained flat at $$0.20 during midday trading on Friday. The company had a trading volume of 2,334,905 shares, compared to its average volume of 7,515,342. The company has a market capitalization of $1.98 million, a price-to-earnings ratio of -0.07 and a beta of 1.01. Ritter Pharmaceuticals has a 1-year low of $0.15 and a 1-year high of $1.35. The firm has a 50 day simple moving average of $0.19 and a 200 day simple moving average of $0.49.

Ritter Pharmaceuticals (NASDAQ:RTTR) last issued its quarterly earnings data on Wednesday, November 13th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.23).

Separately, ValuEngine upgraded Ritter Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, September 30th.

About Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance.

Read More: How much money do you need to begin day trading?

Receive News & Ratings for Ritter Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.